Plus Therapeutics, Inc.

NasdaqCM:PSTV Stock Report

Market Cap: US$7.1m

Plus Therapeutics Management

Management criteria checks 2/4

Plus Therapeutics' CEO is Marc Hedrick, appointed in May 2004, has a tenure of 20.5 years. total yearly compensation is $1.13M, comprised of 49.1% salary and 50.9% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth $24.51K. The average tenure of the management team and the board of directors is 5 years and 4.3 years respectively.

Key information

Marc Hedrick

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage49.1%
CEO tenure20.5yrs
CEO ownership0.3%
Management average tenure5yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating

Oct 07

Plus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October end

Sep 22

Plus Therapeutics GAAP EPS of -$0.24 misses by $0.02

Jul 21

CEO Compensation Analysis

How has Marc Hedrick's remuneration changed compared to Plus Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$13m

Jun 30 2024n/an/a

-US$13m

Mar 31 2024n/an/a

-US$12m

Dec 31 2023US$1mUS$556k

-US$13m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$17m

Mar 31 2023n/an/a

-US$21m

Dec 31 2022US$955kUS$535k

-US$20m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$2mUS$510k

-US$13m

Sep 30 2021n/an/a

-US$13m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$1mUS$510k

-US$8m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$2m

Mar 31 2020n/an/a

-US$2m

Dec 31 2019US$867kUS$510k

-US$4m

Sep 30 2019n/an/a

-US$7m

Jun 30 2019n/an/a

-US$11m

Mar 31 2019n/an/a

-US$9m

Dec 31 2018US$615kUS$510k

-US$11m

Sep 30 2018n/an/a

-US$18m

Jun 30 2018n/an/a

-US$19m

Mar 31 2018n/an/a

-US$24m

Dec 31 2017US$846kUS$500k

-US$27m

Compensation vs Market: Marc's total compensation ($USD1.13M) is above average for companies of similar size in the US market ($USD652.28K).

Compensation vs Earnings: Marc's compensation has increased whilst the company is unprofitable.

CEO

Marc Hedrick (61 yo)

20.5yrs

Tenure

US$1,134,027

Compensation

Dr. Marc H. Hedrick, M.D., M.B.A., serves as President of Plus Therapeutics, Inc. (also known as Cytori Therapeutics, Inc.) since May 2004 and has been its Chief Executive Officer since April 2, 2014. Dr....

Leadership Team

NamePositionTenureCompensationOwnership
Marc Hedrick
President20.5yrsUS$1.13m0.35%
$ 24.5k
Andrew Sims
VP of Finance & CFO4.8yrsUS$539.23k0.17%
$ 11.8k
Desiree Smith
Corporate Controller5yrsno datano data
John Fraser
Chief Scientistno datano datano data

5.0yrs

Average Tenure

60.5yo

Average Age

Experienced Management: PSTV's management team is seasoned and experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marc Hedrick
President22.1yrsUS$1.13m0.35%
$ 24.5k
Robert Lenk
Independent Director4.6yrsUS$52.87k0.50%
$ 35.2k
Gregory Petersen
Independent Director4.8yrsUS$80.37k0.83%
$ 58.7k
Richard Hawkins
Independent Chairman of the Board16.9yrsUS$102.87k0.26%
$ 18.2k
Howard Clowes
Independent Director4.6yrsUS$75.37k0.45%
$ 31.8k
Andrew Brenner
Member of Scientific Advisory Board4yrsno datano data
Nicholas Butowski
Member of Clinical Advisory Board4.1yrsno datano data
An van Es-Johansson
Independent Director4.8yrsUS$65.37k0%
$ 0
Russell Lonser
Member of Clinical Advisory Board4.1yrsno datano data
Alireza Mohammadi
Member of Clinical Advisory Board4.1yrsno datano data
Michael Vogelbaum
Member of Clinical Advisory Board4.1yrsno datano data
Manish Aghi
Member of Clinical Advisory Board4.1yrsno datano data

4.3yrs

Average Tenure

67yo

Average Age

Experienced Board: PSTV's board of directors are considered experienced (4.3 years average tenure).